News Column

SHL Telemedicine reports first quarter 2013 financial results

May 20, 2014

newsbox.ch

Press release (German press release on page 5)



SHL Telemedicine reports first quarter 2014 financial results


Revenues up by 49.3 % to USD 10.6 million (USD 7.1 million in Q1 2013)EBITDA reached USD 2.0 million (USD 1.4 million in Q1 2013)Germany revenue tripled year over year, contributing 43.4% of total revenuesReceived marketing approvals for the smartheartTMin Japan and ChinaAccelerated revenue growth. Increasing revenue outlook to over 30% growth in 2014


Tel Aviv/Zurich, 21 May 2014-SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY), a leading provider and developer of advanced personal telemedicine solutions, today announced results for the first quarter ended 31 March 2014.


Erez Alroy, Co-CEO of SHL, commented: "We have started the year on solid footing and have successfully accelerated our revenue growth. As a result, we are increasing our revenue outlook to over 30% growth for the year. We are confident this momentum in our business will continue for the remainder of 2014."


Business Review

SHL strengthened its position as a leading provider of telehealth services in Germany through the broadening of its institutional services portfolio and customer base. The Company recently appointed Mr. Martin Lehner as Managing Director of SHL Germany. Prior to joining SHL, he served as CEO and President of Amoena, a leading medical products company and as Executive Vice President at Elan Group.


In Israel, SHL's business showed another strong quarter with improved margins.


SHL is progressing in the commercial rollout of its telehealth services in India. And in the U.S., the Company has started developing channels for the smartheartTM platform.


In May, SHL received the China Food and Drug Administration ("CFDA") approval for the marketing of the smartheartTM in China, which closely follows the receipt of the Japanese PMDA Pre-Market Certification for marketing the smartheartTM. The smartheartTM has already received marketing approvals in Europe and the U.S.


During the quarter, SHL launched a Level 1 American Depository Receipt (ADR) program in the United States. The ADRs are traded over-the-counter under the ticker symbol SMDCY. Each ADR represents one ordinary share in SHL Telemedicine. The Company's ordinary shares continue to trade on the SIX Swiss Exchange under the symbol "SHLTN".


Financial Highlights

During the first quarter 2014, revenues increased considerably primarily due to the growth in the Company's German business, following the acquisition of almeda. Even with the increased investments in geographical expansion, SHL's financial performance has improved significantly with improved gross and operating margins.


Revenues for the first quarter amounted to USD 10.6 million compared with USD 7.1 million in the first quarter of 2013. This represents an increase of 49.3% and 42.3% at constant exchange rates*.


Gross profit for the quarter amounted to USD 6.0 million (56.6% of revenues) compared with USD 3.7 million (52.1% of revenues) in the first quarter of 2013.


EBITDA for the quarter amounted to USD 2.0 million (18.9% of revenues) with EBIT for the quarter amounting to USD 0.4 million (3.8% of revenues) compared with EBITDA of USD 1.4 million (19.7% of revenues) and EBIT of USD 0.2 million (2.8% of revenues) in the first quarter of 2013.


Net income for the quarter amounted to USD 0.0 million (USD 0.00 per share) compared with a net loss of USD 0.3 million (USD 0.03 per share) in Q1 2013.


Cash flow for the quarter includes cash used in operations of USD 2.4 million. Excluding USD 5.2 million received from Philips in the first quarter of 2013, which was the last payment related to the Raytel transaction, cash used in operations during the quarter amounted to USD 1.3 million. The decrease in operating cash flow this quarter is the result of one-time working capital requirements at almeda, for which SHL received USD 2.9 million upfront at the end of 2013. Cash, cash equivalents and marketable securities amounted to USD 25.1 million at March 31, 2014.


Balance sheet included total assets at 31 March 2014 of USD 108.2 million with shareholders' equity amounting to USD 68.9 million (63.7% of balance sheet) compared to total assets of USD 108.5 million with shareholders' equity amounting to USD 68.9 million at 31 December 2013.



SHL Telemedicine - consolidated key figures -Q1 2014



in USD million (except per share amounts)



Q1 2014



Q1 2013



% change



Q1 2014 (constant currency)



% change



Revenues



10.6



7.1



49.3%



10.1



42.3%



Gross profit



6.0



3.7



62.2%



5.7



54.1%



%



56.6%



52.1%



56.4%





EBIT



0.4



0.2



100.0%



0.4



100.0%



%



3.8%



2.8%



4.0%





EBITDA



2.0



1.4



42.9%



1.9



35.7%



%



18.9%



19.7%



18.8%





Net income/(loss)



0.0



(0.3)



n.a.



0.1



n.a.



Basic EPS/ LPS)



0.00



(0.03)



n.a.



0.00



n.a.




* Constant currency - In order to enable meaningful comparison between the results, they are also presented at constant currency exchange rates. These are calculated by translating the 2014 results using the average 2013 exchange rates instead of the current period exchange rates. Management believes that this presentation enables a more meaningful comparison between the periods due to the significant fluctuations in NIS/USD/EUR exchange rates.


Revenues by geographic distribution -Q1 2014





Israel



Germany





USD m



% of total



USD m



% of total



Q1 2014



6.0



56.6%



4.6



43.4%



Q1 2013



5.6



78.9%



1.5



21.1%



Q1 2014 (constant currency exchange rates)



5.7



56.4%



4.4



43.6%



% change in constant currency



1.8%





193.3%







Conference Call, today, 21 May, 4.00 pm CET

SHL will hold a conference call to discuss the Q1 results today at 4.00 pm CET. Erez Alroy, Co-CEO, and Eran Antebi, CFO, will host the call. Dial-in numbers are as follows:




From Europe



+41 (0)58 310 50 00



From UK



+44 (0)203 059 58 62



From US



+1 (1)631 570 5613



From Israel



Toll free: 1 80 921 44 27/Local: +972 3763 1173




Slides are available at

http://www.shl-telemedicine.com/investors-relations/financial-reports/


IR Agenda 2014



August 20, 2014



Q2 Results



November 19, 2014



Q3 Results




About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information please visit our web site at www.shl-telemedicine.com.



Contacts:



Erez Alroy

Co-CEO

P:+972 3 5612212,

ereza@shl-telemedicine.com




Martin Meier-Pfister

IRF Communications

P: +41 43 244 81 40

shl@irfcom.ch




Garth Russell/Elizabeth Barker

KCSA Strategic Communications

P: 212-896-1250 / 212-896-1239

grussell@kcsa.com / barker@kcsa.com




Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.






Medienmitteilung


SHL Telemedicine prÄsentiert Ergebnisse fÜr das erste Quartal 2014


Umsatz stieg um 49.3% auf USD 10.6 Mio. (Q1 2013: USD 7.1 Mio.)EBITDA erreichte USD 2.0 Mio. (Q1 2013: USD 1.4 Mio.)ErtrÄge in Deutschland verdreifachten sich im Jahresvergleich und tragen nun 43.4% zum Gesamtumsatz beiMarktzulassungen fÜr SmartheartTM in China und JapanErtragswachstum beschleunigt. Neue Umsatzprognose: 30% Wachstum 2014


Tel Aviv/ZÜrich, 21. Mai 2014-SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY), ein fÜhrender Entwickler und Anbieter moderner personalisierter Telemedizin-LÖsungen, hat heute die Ergebnisse fÜr das 1. Quartal per 31. MÄrz 2014 vorgelegt.


Erez Alroy, Co-CEO von SHL, kommentierte: «Wir hatten einen guten Start ins Jahr 2014 und haben den Umsatz weiter gesteigert. Auf der Basis haben wir unsere Prognose fÜr das Umsatzwachstum 2014 auf 30% angehoben. Die Chancen sind intakt, dass wir diese positive Dynamik im verbleibenden Jahr weiter nutzen kÖnnen.»


GeschÄftslage

SHL baute die Position als fÜhrender Anbieter von telemedizinischen Dienstleistungen in Deutschland via den Ausbau des institutionellen Service-Portfolios und der Kundenbasis weiter aus. Martin Lehner ist kÜrzlich zum neuen GeschÄftsfÜhrer fÜr das DeutschlandgeschÄft von SHL ernannt worden. Lehner war CEO und PrÄsident von Amoena, ein fÜhrender Anbieter von Medizinprodukten, und Executive Vice President bei der Elan Gruppe.


In Israel lief das GeschÄft von SHL im 1. Quartal wiederum rund, die UmsÄtze nahmen zu. In den USA investierte SHL in die Entwicklung verschiedener AbsatzkanÄle fÜr die SmartheartTM-Plattform.


Gefolgt von der PMDA-Markzulassung (Pre-Market Certification) in Japan erhielt SHL im Mai von der chinesischen ZulassungsbehÖrde CFDA (China Food and Drug Administration) die Marktzulassung fÜr den SmartheartTM in China. Bereits zugelassen ist der SmartheartTM in Europa und den USA.


Im 1. Quartal lancierte SHL ein Level-1-American-Depository-Receipt-(ADR)-Programms in den USA. Die ADRs werden am Over-the-Counter-(OTC)-Markt gehandelt. Jedes ADR ist mit einer normalen SHL Aktie gleichzusetzen. Die Aktien von SHL werden wie bis anhin der SIX Swiss Exchange unter dem Symbol "SHLTN" gehandelt.


Finanzkennzahlen

SHL hat den Umsatz im 1. Quartal 2014 deutlich gesteigert. HauptgrÜnde hierfÜr waren das Wachstum im DeutschlandgeschÄft im Zuge der Akquisition von almeda. Trotz der hÖheren Investitionen bedingt durch die geographische Expansion konnte SHL Bruttomarge und operative Marge verbessern und die Finanzposition deutlich stÄrken.


Der Umsatz belief sich im 1. Quartal 2014 auf USD 10.6 Mio. gegenÜber USD 7.1 Mio. im Vorjahreszeitraum. Dies entspricht einem Anstieg von 49.3% bzw. 42.3% zu konstanten Wechselkursen*.


Der BruttogewinnfÜr das 1. Quartal 2014 betrug USD 6.0 Mio. (56.6% des Umsatzes) gegenÜber USD 3.7 Mio. (52.1% des Umsatzes) im ersten Quartal 2013.


Der EBITDAlag im 1. Quartal 2014 bei USD 2.0 Mio. (18.9% vom Umsatz) und der EBIT bei USD 0.4 Mio. (3.8% des Umsatzes). Im Vorjahreszeitraum belief sich der EBITDA auf USD 1.4 Mio. (19.7% des Umsatzes) und der EBIT auf USD 0.2 Mio (2.8% vom Umsatz) im 1. Quartal von 2013.


Der Reingewinnbetrug im 1. Quartal USD 0.0 Mio. (USD 0.00 pro Aktie), gegenÜber einem Nettoverlust von USD 0.3 Mio. (USD 0.03 pro Aktie) in der Vorjahresperiode.


Cashflow.Der NettoliquiditÄtsbedarf fÜr die operative TÄtigkeit betrug im 1. Quartal USD 2.4 Mio. Im Vorjahreszeitraum hatte er nach Abzug der Schlussrate der Raytel-Transaktion Über USD 5.2 Mio. von Philips bei USD 1.3 Mio. gelegen. Der operative Cash drain im ersten Quartal 2014 war auf einen einmaligen Betriebskapitalbedarf bei almeda zurÜckzufÜhren, fÜr den SHL bereits Ende 2013 vorab USD 2.9 Millionen bereitgestellt hatte. Barmittel und bÖrsengÄngige Wertpapiere beliefen sich zum 31. MÄrz 2014 auf USD 25.1 Mio.


Bilanz.Die Aktiva von SHL beliefen sich zum 31. MÄrz 2014 auf USD 108.2 Mio., wobei USD 68.9 Mio. bzw. 63.7% der Bilanzsumme auf Eigenkapital entfielen. Zum 31. Dezember 2013 betrugen die Aktiva USD 108.5 Mio., davon USD 68.9 Mio. Eigenkapital.







Balance-Sheets (USD thousands)



31.3.2014



31.3.2013



31.12.2013





Unaudited



Unaudited



Audited



Cash and cash equivalents



5,939



12,969



8,732



Available-for-sale investments



19,116



16,160



19,661



Trade receivables



14,134



11,965



10,479



Inventory



1,213



457



869



Other current assets



8,081



6,466



8,014



Current Assets



48,483



48,017



47,755











Non-Current Assets



11,372



12,437



11,632











Property and equipment, net



15,600



15,239



15,982











Intangible assets, net



32,739



23,092



33,146











Total Assets



108,194



98,785



108,515











Credit from banks and current maturities



11,156



8,522



10,477



Deferred revenues



590



110



330



Trade payables



1,925



1,214



1,433



Provisions



-



1,067



-



Other accounts payable



4,472



4,240



4,568



Other liabilities



2,007



-



2,504



Current liabilities



20,150



15,153



19,312











Long-term loans



17,095



19,506



18,205



Deffered revenues



1,244



1,488



1,283



Employee benefit liabilities



834



932



805



Non-current liabilities



19,173



21,926



20,293











Total liabilities



39,323



37,079



39,605



Equity:









Issued capital



31



31



31



Additional paid-in capital



95,069



94,488



95,014



Treasury shares



(2,753)



(2,956)



(2,774)



Foreign currency translation reserve



6,130



3,002



6,366



Capital reserve for available-for-sale investments and actuarial gains



1,533



860



1,415



Accumulated deficit



(31,139)



(33,719)



(31,142)



Total equity



68,871



61,706



68,910











Total liabilities and equity



108,194



98,785



108,515





Statements of Income

(USD thousands, except per share data)



Q1 14



Q1 13



2013





Unaudited



Unaudited



Audited



Revenues



10,643



7,140



29,674











Depreciation and amortization



604



571



2,127



Cost of revenues



4,060



2,896



11,607



Gross Profit



5,979



3,673



15,940











Research and development costs, net



597



436



2,206



Selling and marketing expenses



2,732



2,059



8,787



General and administrative expenses



2,284



1,000



10,341



Gain from almeda acquisition



-



-



(8,492)



Operating income



366



178



3,098











Financial income



193



333



1,072



Financial expenses



(244)



(645)



(2,631)



Income (loss) before taxes on income



315



(134)



1,539



Taxes on income (tax benefit)



312



211



(693)











Net income (loss)



3



(345)



2,232











Basic and diluted income (loss) per share



-



(0.03)



0.22




Other Comprehensive income not to be reclassified to profit or loss in subsequent periods:










Foreign currency translation reserve



(236)



942



4,306



Actuarial gain



-



-



233





(236)



942



4,539



Other Comprehensive income to be reclassified to profit or loss in subsequent periods









Transfer to the statement of income in respect of available-for-sale investments



(56)



(32)



146



Gain on available-for-sale investments



174



44



188





118



12



334



















Total comprehensive income(loss)



(115)



609



7,105









Statements of Cash Flows (USD thousands)



Q1 2014




Q1 2013



2013





Unaudited



Unaudited



Audited



Net income (loss)



3



(345)



2,232



Adjustment required to reconcile net income (loss) to net cash provided by (used in) operating activities



(2,376)



4,281



400



Net Cash provided by (used in) Operating Activities



(2,373)



3,936



2,632











Purchase of property and equipment



(383)



(603)



(2,200)



Investment in intangible assets



(398)



(485)



(1,878)



Acquisition of almeda



-



-



2,920



Proceeds from sale of property and equipment



-



-



29



Purchase of available-for-sale investments



(1,926)



(448)



(8,511)



Proceeds from sale of available-for-sale investments



2,444



749



6,402



Net Cash used in Investing Activities



(263)



(787)



(3,238)











Proceeds from exercise of options



5



40



486



Short-term bank credit, net



714



(243)



1,053



Payment of long-term loans



(869)



(776)



(3,267)



Treasury shares purchased



-



(36)



(36)



Net Cash used in Financing Activities



(150)



(1,015)



(1,764)



Effect of exchange rate changes on cash and cash equivalents



(7)



222



489



Increase (decrease) in cash and cash equivalents



(2,793)



2,356



(1,881)



Cash and cash equivalents at the beginning of the period



8,732



10,613



10,613



Cash and Cash equivalents at the end of the period



5,939



12,969



8,732







Press Release (PDF)







Provider

Channel

Contact
Tensid Ltd., Switzerland

www.tensid.ch





newsbox.ch

www.newsbox.ch





Provider/Channel related enquiries

marco@tensid.ch

+41 41 763 00 50


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Tensid Regulatory